Analysts Offer Predictions for PRLD Q3 Earnings

Key Points

• HC Wainwright's Earnings Estimates: Analysts predict Prelude Therapeutics will post a Q3 2025 earnings per share (EPS) of ($0.35), maintaining a "Buy" rating with a target price of $5.00.
• Recent Stock Performance: Prelude Therapeutics shares recently opened at $1.17, with a 52-week range between $0.61 and $2.25, reflecting a current market cap of $66.22 million.
• Institutional Ownership: Approximately 79.72% of Prelude Therapeutics' stock is owned by institutional investors, indicating significant institutional confidence in the company's future prospects.

Prelude Therapeutics Incorporated (NASDAQ:PRLD - Free Report) - Equities researchers at HC Wainwright issued their Q3 2025 earnings per share (EPS) estimates for shares of Prelude Therapeutics in a note issued to investors on Tuesday, September 23rd. HC Wainwright analyst R. Burns expects that the company will earn ($0.35) per share for the quarter. HC Wainwright currently has a "Buy" rating and a $5.00 target price on the stock. The consensus estimate for Prelude Therapeutics' current full-year earnings is ($1.81) per share. HC Wainwright also issued estimates for Prelude Therapeutics' Q4 2025 earnings at ($0.33) EPS, FY2025 earnings at ($1.51) EPS, Q1 2026 earnings at ($0.30) EPS, Q2 2026 earnings at ($0.31) EPS, Q3 2026 earnings at ($0.31) EPS, Q4 2026 earnings at ($0.32) EPS and FY2026 earnings at ($1.24) EPS.

Separately, JMP Securities cut their price objective on Prelude Therapeutics from $4.00 to $3.00 and set a "market outperform" rating for the company in a research report on Monday, August 18th. Two analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the stock presently has an average rating of "Buy" and a consensus price target of $4.00.

Prelude Therapeutics Stock Performance

Shares of PRLD stock opened at $1.17 on Thursday. Prelude Therapeutics has a 1 year low of $0.61 and a 1 year high of $2.25. The business's fifty day moving average is $1.02 and its 200-day moving average is $0.89. The stock has a market cap of $66.22 million, a PE ratio of -0.71 and a beta of 1.25.

Prelude Therapeutics (NASDAQ:PRLD - Get Free Report) last released its quarterly earnings results on Thursday, August 14th. The company reported ($0.41) earnings per share for the quarter, beating analysts' consensus estimates of ($0.45) by $0.04.

Hedge Funds Weigh In On Prelude Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Shay Capital LLC bought a new position in Prelude Therapeutics during the second quarter valued at about $61,000. Jane Street Group LLC acquired a new position in shares of Prelude Therapeutics during the 2nd quarter valued at about $74,000. Marshall Wace LLP acquired a new position in shares of Prelude Therapeutics during the 2nd quarter valued at about $34,000. XTX Topco Ltd raised its stake in shares of Prelude Therapeutics by 72.4% in the 2nd quarter. XTX Topco Ltd now owns 42,573 shares of the company's stock valued at $34,000 after acquiring an additional 17,873 shares in the last quarter. Finally, Y Intercept Hong Kong Ltd acquired a new stake in Prelude Therapeutics in the 2nd quarter worth approximately $39,000. Institutional investors own 79.72% of the company's stock.

About Prelude Therapeutics

Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.